Phase 4
Completed N=140
Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
Source: ClinicalTrials.gov NCT03114995 ↗Enrolled (actual)
140
Serious AEs
0.0%
Results posted
Jun 2018
Primary outcomePrimary: Area Under Curve of Serial Cardiac Biomarkers — 197.2; 38.0; 121.4; 252.5 Hours*ng/ml
◆ Published Evidence
Highly cited
351citations · ~20 / year
Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
Summary
Investigators aimed to test the beneficial effect of tirofiban, a GPIIb/IIIa antagonist, for Non-ST-Elevation Acute Coronary Syndrome Patients who has high resistance to clopidogrel.
Linked Publications (5)
-
Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
-
Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality.
-
Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry.
-
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
-
Prognostic significance of small troponin I rise after a successful elective percutaneous coronary intervention of a native artery.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Area Under Curve of Serial Cardiac Biomarkers |
197.2; 38.0; 121.4; 252.5; 92.7; 185.6 | — |
| SECONDARY Percentage of Participants With Periprocedural Myonecrosis |
16; 15; 26; 11; 10; 25 | — |
Eligibility Criteria
Inclusion Criteria
- diagnosed with NSTE-ACS who need PCI
- loaded with aspirin and clopidogrel at least 6 h before the procedure
Exclusion Criteria
- thrombocytopenia (platelet count <100,000/μL)
- history of hemorrhagic stroke
- history of ischemic stroke in the recent 2 year
- history of major surgery 6 months prior
Data sourced from ClinicalTrials.gov (NCT03114995) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.